GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (BSP:B1ME34) » Definitions » Interest Income

BeiGene (BSP:B1ME34) Interest Income : R$258 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is BeiGene Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. BeiGene's interest income for the three months ended in Dec. 2024 was R$48 Mil. Its interest income for the trailing twelve months (TTM) ended in Dec. 2024 was R$258 Mil.

BeiGene Interest Income Historical Data

The historical data trend for BeiGene's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Interest Income Chart

BeiGene Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 275.28 362.63 291.85

BeiGene Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 79.74 80.47 71.23 58.94 47.64

BeiGene Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was R$258 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeiGene Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (BSP:B1ME34) » Definitions » Interest Income
Comparable Companies
ALNY BNTX SMMT INSM BMRN RPRX MRNA INCY EXEL ASND VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB XKRX:068270 HKSE:02269 XKRX:196170 OCSE:GMAB
Traded in Other Exchanges
BEIGF:USA ONC:USA 06160:Hong Kong 49B:Germany 49B:Germany 49BA:Germany 49BA:Germany 688235:China
Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
Website
https://www.beigene.com
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

BeiGene Headlines

No Headlines